{"id":1629,"date":"2020-06-16T16:10:43","date_gmt":"2020-06-16T21:10:43","guid":{"rendered":"http:\/\/blogs.uml.edu\/m2d2\/?p=1629"},"modified":"2020-06-19T08:37:41","modified_gmt":"2020-06-19T13:37:41","slug":"m2d2-resident-companies-at-bio-digital","status":"publish","type":"post","link":"https:\/\/blogs.uml.edu\/m2d2\/2020\/06\/16\/m2d2-resident-companies-at-bio-digital\/","title":{"rendered":"Two M2D2 Resident Companies Present at BIO Digital"},"content":{"rendered":"\n

During the second week of June, two M2D2 resident companies took part in this year\u2019s BIO Digital Convention. LivOnyx Inc.<\/a> and Versatope Therapeutics<\/a> both presented their progress and innovative solutions during BIO Digital Week, a virtual convention featuring interactive sessions covering therapeutics, digital health, patient advocacy, and more. Both of these startups are working on solutions that are very relevant during the COVID-19 pandemic.<\/p>\n\n\n\n\n\n\n\n

About BIO\nDigital <\/strong><\/h2>\n\n\n\n

The BIO International Convention is an annual convention that\ninvolves over 7,000 participants from 64 countries who share thought-provoking\nconversations, engage in one-on-one partnering, and showcase innovative ideas. <\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n

In light of the COVID-19 pandemic and the recommended safety\nprecautions, this year\u2019s convention was completely virtual. Nonetheless, the event\nallows these startups a chance to gain visibility and create important\npartnerships. Both LivOnyx and Versatope made the most of the opportunity for\ninternational exposure.   <\/p>\n\n\n\n

LivOnyx<\/strong><\/h2>\n\n\n\n

LivOnyx Inc.<\/a> is working on a novel, fully automated device, and antiseptic that will reduce the spread of infections in healthcare and other public places. Their LivOnyx thinSpray™ hand sanitizing system aims to work quickly while leaving hands dry and simultaneously eliminating clinically important pathogens. <\/p>\n\n\n\n

\"\"<\/figure><\/div>\n\n\n\n

There is a growing need within healthcare for a quick and thorough\nsolution that eliminates the spread of infections. Presenting at BIO Digital has\nshed more light on LivOnyx and the importance of their innovation. Carmela Mascio,\nPresident & Co-Founder, shared her reaction after speaking at BIO Digital. <\/p>\n\n\n\n

\u201cThe conference organizers put in a tremendous amount of\nwork in organizing an incredible and interactive conference for attendees from around\nthe world. The LivOnyx team is grateful to the BIO community to for the\nopportunity to participate in the Startup Stadium, have access to important\npanel discussions, and the ability to set up one-on-one meetings through the\nBIO One-on-One Partnering Portal.\u201d<\/p>\n\n\n\n

Versatope\nTherapeutics<\/strong><\/h2>\n\n\n\n

Versatope Therapeutics<\/a>\ndeveloping a universal flu vaccine. They are creating a transformative and\nhighly effective platform for improving immunotherapy and vaccines. As a sign\nof their accelerated progress. Versatope recently announced an\ninfluenza vaccine development agreement<\/a> with a Netherlands-based company,\nIntravacc. <\/p>\n\n\n\n

Versatope has recognized the growing need for a universal\nvaccine that could eliminate the need for yearly immunizations and offer greater\nprotection against a wider range of viruses. Christopher Locher, CEO of\nVersatope Therapeutics, shares his experience from this year\u2019s BIO Digital\nconference. <\/p>\n\n\n\n

\"versatope<\/figure><\/div>\n\n\n\n

\u201cVersatope has been attending the BIO conference each year since it was founded to present their company at the start-up session, network with attendees, and attend the scientific panel discussions. This year the virtual conference has highlighted the importance of addressing the need for infectious disease vaccines, diagnostics, and case monitoring and a rapid response to global pandemics.\u201d<\/p>\n\n\n\n

Continual Success Surrounding M2D2 Resident Companies<\/strong><\/h2>\n\n\n\n

Over the past 6 months, we have seen many advancements and\nsuccess from M2D2 Resident Companies. Director of Operations Mary Ann Picard\nshares her continued appreciation and support for these hard-working companies.\n\u201cSeveral of our resident companies are committed to finding solutions for the\ncurrent pandemic. We are thrilled to see both LivOnyx and Versatope recognized\nfor their innovative ideas and solutions at this year\u2019s BIO Digital conference.\nWe look forward to seeing their continued growth and advancements.\u201d<\/p>\n\n\n\n

More about Versatope Therapeutics:<\/strong><\/p>\n\n\n\n

UMass\nLowell Receives Funding from MLSC to Advance New Continuous Manufacturing\nProcess<\/a><\/p>\n\n\n\n

Meet\nan M2D2 $200K Challenge Finalist: Versatope<\/a><\/p>\n\n\n\n

2018\nM2D2 $200K Challenge Winners Announced<\/a><\/p>\n\n\n\n

Follow Versatope Therapeutics on social media:<\/strong><\/p>\n\n\n\n

LinkedIn<\/a><\/p>\n\n\n\n

Twitter<\/a><\/p>\n\n\n\n

More About LivOnyx Inc.: <\/strong><\/p>\n\n\n\n

M2D2\nresident company LivOnyx named a 2019 winner in MLSC MassNextGen Initiative<\/a><\/p>\n\n\n\n

Follow LivOnyx Inc. on social media:<\/strong><\/p>\n\n\n\n

Twitter<\/a><\/p>\n\n\n\n

LinkedIn<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

During the second week of June, two M2D2 resident companies took part in this year\u2019s BIO Digital Convention. LivOnyx Inc. and Versatope Therapeutics both presented their progress and innovative solutions during BIO Digital Week, a virtual convention featuring interactive sessions … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":328,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/1629"}],"collection":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/users\/328"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/comments?post=1629"}],"version-history":[{"count":2,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/1629\/revisions"}],"predecessor-version":[{"id":1634,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/posts\/1629\/revisions\/1634"}],"wp:attachment":[{"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/media?parent=1629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/categories?post=1629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.uml.edu\/m2d2\/wp-json\/wp\/v2\/tags?post=1629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}